Tuesday saw the UCI announce the races that will make up the 2017 WorldTour calendar. All the regular names are there, including races run by the ASO, which resolved its conflict with the sport’s governing body earlier this year.
As part of the WorldTour reforms the current group of races will be joined by an influx of varied new ones, ten of them in fact, which range from the sandy, windswept Tour of Qatar to the muddy, windswept Omloop Het Nieuwsblad, among others.
Judging by the events involved it seems there are a myriad of reasons involved in their selection.
The Cadel Evans Road Race attracted nine WorldTeams this season and looks a logical enough addition given its proximity to the Tour Down Under
The money grabs – the Tour of Qatar and the 1-year-old Abu Dhabi Tour fill an empty slot in the WorldTour calendar between January’s Tour Down Under and March’s Paris-Nice but the racing is hardly vintage.
Spring classics Omloop Het Nieuwsblad, Strade Bianche and Dwars door Vlaanderen provide great racing, though perhaps just the first two would have done.
Turkey has been linked for a while, though its inclusion is less sensible than ever given the political situation in the country and the fact that the new organisers oversaw what was hardly a success this season, with only two WorldTeams showing up.
Finally, Eschborn-Frankfurt, California and RideLondon all hit important markets, with American long overdue a top-level race. The Tour of Britain would perhaps have been a better choice than RideLondon, though that likely would’ve caused a similar problem for local teams as California’s inclusion could.
All races have been awarded with three-year licenses, in accordance with a new application process, something which the UCI claim was “was met with significant interest from race organisers”.
This new-look WorldTour is a far cry from the unpopular reforms originally proposed way back in 2014, which featured shortened races and a confusing B-team system. While these additions certainly seem a better idea than those reforms, there are – as ever – a number of problems and questions that arise as a result of this expansion.
The increased number of calendar clashes is the first problem that springs to mind. With 37 events spread over 176 days there will now be a further 14 racedays during which WorldTour events clash with each other, with seven already on the calendar. The 2014 reforms called for fewer clashes, a plan which has obviously been abandoned.
Many of these clashes are easy enough to deal with – for instance, teams already send squads to the Ardennes and the Tour of Turkey with no problems. A bigger problem will be the weekend of July 30th, which sees three events crammed in. Clásica San Sebastián is held on Saturday, the same day the Tour de Pologne starts and a day before the RideLondon-Surrey Classic.
It’s a calendar that FDJ boss Marc Madiot has described as making “no sense”, adding that his squad wouldn’t miss out on French races to meet the WorldTour’s requirements: “it’s part of our duty to support local races as well.” This sentiment is likely to be echoed by other teams, while his thoughts about the UCI’s proposed participation rules (a minimum of ten WorldTeams at new WorldTour events) have already been stated by the AIGCP (the association of pro teams).
At the time of writing the AIGCP has yet to release a statement on the newly-announced reforms, though it’s easy to get a sense of what it would be, given their response to the UCI’s June 23rd press release, which first brought up the subject of participation rules.
“The AIGCP maintains that it is not the case that the PCC approved the principle of setting up for newly-promoted WorldTour events… nor is it the case that the PCC agreed to examine such a proposal at the next meeting of the PCC. On the contrary, it was confirmed, as was approved by the Management Committee and the PCC in 2015, that newly-promoted WorldTour events bear the full responsibility for securing participation of at least 10 WorldTeams with no coercive mechanisms.”
Right now it is unclear how this rule would be enforced. Would the UCI strongarm teams into turning up in Turkey? How would they pick who goes and who doesn’t? The other races (with the exception of Frankfurt at 4) already attract between 7 and 12 WorldTeams, and there probably wouldn’t be too much trouble getting to 10.
One final point can be made about the balance of the calendar. With the new additions the calendar looks even more front-heavy. Nine of the new additions take place before July, in addition to 17 of the 27 current races.
Personally I would’ve liked to see the Arctic Race of Norway, Paris-Tours and Milano-Torino promoted to give the August and September calendar a boost. The latter two races certainly strike me as more deserving from a racing standpoint than some of the UCI’s chosen ten.
Ultimately it looks as though little will change from our point of view – these races will outwardly remain largely the same, though the additional WorldTour points will make a difference for teams, whether or not they choose to attend.
But it does seem like the UCI have inadvertently created another class of races, not quite WorldTour and not Continental-level either. The races are presumably paying similar fees to the current WorldTour races, only to see 7 less top tier teams competing.
The question of cycling’s top tier and how to organise it fairly and positively for all has yet to be solved, and this latest move from the UCI isn’t going to be the final fix. Indeed, it’s probable that the WorldTour problem will never be solved to the satisfaction of everybody involved. One thing is for sure – I certainly don’t think this is the answer.
Thursday’s news of Simon Yates’ positive test for asthma drug Terbutaline capped a horrific week for British Cycling, with the various Shane Sutton-related scandals that also exploded this week still ongoing. Combined, the scandals have made for a disastrous run-in to the Tour de Yorkshire, one of the flagship events of the British racing calendar..
Others with more interest in track cycling and more knowledge of women’s cycling than I have analysed and picked apart the Sutton scandals better than I ever could (Anne-Marije Rook, Sarah Connolly, Helen Pidd), but the focus here will be on the Yates case.
On Thursday British newspaper The Daily Mail teased the positive test of a British ‘track star’ who was gunning for an Olympic road race spot, adding that the test was recorded at a French race in March. Twitter detectives (me included) swiftly concluded that it was likely Simon Yates, an assumption which was soon confirmed by the paper.
The drug that the 23-year-old had tested positive for was Terbutaline, one of the few not yet familiar to cycling fans, doing so on stage six of Paris-Nice. His team, Orica-GreenEdge confirmed this via press release, noting that use of the substance was declared on the Doping Control Form when Yates took the test. The team goes on to say that they were informed on April 22nd and adding that the reason for the positive test was that “a team doctor made an administrative error by failing to apply for the TUE required.”
At the time of writing, there is much to unpack and Yates’ status is up in the air as he waits for the UCI to review his documentation before they rule on the case. As Terbutaline is not a specified substance (a substance more susceptible to a non-doping explanation), Yates is not provisionally suspended per the UCI’s Anti-doping rules, section 7.9.1.
The drug, and its legality
Before getting to the ins and outs of the case, what is Terbutaline? Put simply, it’s a bronchodilator, a substance which dilates bronchial passages, opening the airways and increasing airflow to the lungs.
When inhaled, it’s fast-acting and the effects can last for six hours – that’s slightly longer than the more common Salbutamol. Basically it’s an asthma medication, also used to delay preterm labour in pregnant women.
A beta2-agonist, the drug is prohibited for use in sports, per WADA’s Prohibited List. As opposed to similar asthma drugs Salbutamol, Formoterol and Salmeterol, which are allowed in some doses without a TUE, Terbutaline use is only allowed if the user has a TUE.
The effects of this group of drugs on athletic performance are much debated, with a number of medical studies contradicting one another. For example, this 1996 study concludes that beta2-agonist do not increase physical performance in top athletes, and this 2011 study found no significant effects on healthy athletes from the drugs.
On the other hand, this 2000 study tells us that Salbutamol increases muscle strength and endurance in non-asthmatics, while this study from the same year notes that Salbutamol improves performance during sub-maximal exercise. Meanwhile, this 2004 study suggests benefits for endurance athletes. It should be noted though, that these studies used far greater quantities of the drug than a regular asthmatic would inhale.
More recent studies suggested that Terbutaline can improve strength and power performance. Even to get those you’d need to take quite high doses of it. Linking back to the guy who is in the news today – it’s not really likely to improve endurance performance, as far as we know.
Asthma in pro cyclists – really?
Whenever a case related to asthma medication comes up, many people react with shock – how could so many athletes, these peak physical specimens, suffer from asthma?
Dr Dickinson, who conducted a study on this subject in 2014, says that this is not so strange after all. He found that 70% of swimmers from the British swim squad have some form of asthma, while a third of Team Sky riders were found to suffer from it. That’s against a national rate in the UK of 8-10%.
Rather than suffering from classic asthma (caused by genetics or environmental factors) though, this is exercise-induced asthma. The symptoms are similar but the condition is instead caused by the heavy, fast breathing induced by exercise. This form of asthma is what Team Sky’s Chris Froome claims to suffer from.
Dickinson reaffirmed his findings when I talked to him.
Exercise-induced asthma, on the spectrum of asthma, is on the milder end of it. Most elite athletes who do have it purely have exercise-induced asthma – they only get it when they’re at the top end of their high intensity exercise, which is increasing their exposure to things that trigger an asthma attack.
The majority of them would be mild to moderate cases. When they’re not training or competing they’re unlikely to suffer.
Chris Froome claimed not to have one, the CIRC Report said they were abused, and Orica-GreenEdge forgot to apply for one at Paris-Nice. Therapeutic use exemptions have been in the news a lot over the years. They are, in effect, special permissions for athletes to use an otherwise prohibited substance in order to treat a legitimate medical condition.
In order to obtain a TUE for Terbutaline, WADA specifies that along with the request itself, an athlete must submit their full medical file (see below for what that entails).
After the CIRC Report found that the UCI’s TUE process was deficient, noting that Froome’s TUE at the 2014 Tour de Suisse was processed by one person. Since then, the UCI has put into place a TUE Committee, a six-person panel, three of which look at each TUE request before a final decision is made about the request.
There are several conditions that must be met before a TUE can be granted, and as a result of the introduction of these measures and the introduction of the TUE Committee, the number of TUEs granted annually by the UCI has decreased year on year (see below for both).
So it’s pretty thorough, right? Seemingly so, but the system can still be gamed as we have seen in athletics with the coach of the Nike Oregon Project, Alberto Salazar.
After a doctor declined her medication in 2004 for the exercise-induced asthma she was experiencing, Salazar set up an appointment at the Nike Oregon Project with a doctor who had an established protocol. The athlete must go to the local track, run around it, work herself up to having an asthma attack, run down the street and up 12 flights of stairs to the office where the doctor “would be waiting to test you”. Fleshman did this, failed her health test, and was duly prescribed the Advair brand for the duration of the racing season when the pollen count was highest, as well as rescue inhaler Albuterol.
There have been no cases like that in cycling (that we know of anyway), but given the history of the sport it would hardly be a surprise.
With this in mind it seems inevitable that we will see questions arise in relation to Yates’ forgotten TUE (and presumed past TUEs). Is his need for Terbutaline legitimate? Or could a TUE be falsified, Salazar-esque, in a bid to obtain the perceived performance gains? It’s a question that can, and has been applied to every case like this in the past – this culture of suspicion is the norm in our sport.
The BBC’s Matt Slater confirmed via Twitter that Yates had not previously had a TUE for Terbutaline. This fact changes things; with no previous TUEs to point to it will be hard, even impossible, for Yates and the team to prove that his use of Terbutaline was in response to a legitimate medical need (presumably Yates was using Salbutamol previously).
Orica admits this was new drug for Simon Yates, no previous TUE for it. Hard to see how he can avoid a sanction.
As for the choice of Terbutaline over Salbutamol, Dickinson notes that the differences in effect between the two are negligible.
Sometimes athletes choose Terbutaline because they don’t get along with Salbutamol – either it’s not working well for them or they get more side-effects. There’s not really, from an asthma treatment point of view, that much difference. The effects can last a bit longer so that might be a reason for a cyclist to use it.
And if you’re wondering, as many are, why Terbutaline usage requires a TUE while other asthma drugs don’t; Dickinson has the answer for that too.
The reason Terbutaline needs a TUE and Salbutamol doesn’t is more down to the way the tests differentiate between oral and inhaled form. With Salbutamol it’s quite clear that if level in urine is above 1000ng/mL it’s likely that you’ve taken an oral dose. Whereas with Terbutaline it’s quite difficult to tell the difference between an oral and inhaled dose, so you can’t differentiate between the two.
Questions about Orica-GreenEdge
The Australian squad, who left the MPCC earlier this year, aren’t exactly known for a history of positive tests, unlike some other teams in the peloton, though this incident does bring the team and their staff into the limelight.
First though, lets consider the “administrative error” claim. Considering that TUE applications are not guaranteed to be accepted, it seems somewhat disingenuous to basically claim that the process was a done deal and that all that was missing was the application itself. Given the strict documentation guidelines laid out above, the granting of a TUE was not a given.
The grave error in communication is a worry – surely the priority is to get the TUE approved first before using the drug? Maybe Yates and other team staff assumed that it was granted, but this case just goes to show how important vigilance and double-checking are with regard to TUEs
Just as troubling has been the team’s employment of Spanish doctor Manuel Rodríguez Alonso. Having worked for ONCE and Mapei in the 1990s, he later worked at QuickStep, where Patrik Sinkewitz named him as a provider of cortisone, human growth hormone and EPO.
Alonso has been employed at the team for several years, though it is unknown whether he is still with the team as the website does not list staff members. Given his history though, the fact that Alonso has been associated with the team doesn’t look great.
Yates was World Champion in the points race at the 2013 Track Worlds
Ultimately my thoughts were that this situation is the result of an honest mistake by the team, as they had claimed. However, the lack of a previous TUE for the drug does muddy the waters somewhat.
The fact that asthma medication does not have a great effect on athletic performance has not stopped cyclists from abusing them in the past. However, it makes no sense that a rider would risk purposely using Terbutaline without a TUE, given the certainty of being caught if tested.
Regardless, considering Yates’ lack of TUE history for the drug, the outlook for him isn’t great. A ban looks likely, though the length should be a matter of months rather than years. Past Terbutaline cases have included a cyclist (4 months), a swimmer (3 months) and a kayaker (2 months).
As ever, it will be some time before this case reaches its conclusion, but we can thank Orica-GreenEdge’s failure to apply for a TUE for bringing the issue to the forefront once again, letting us take another look at this problematic corner of the sport.
WorldTour teams Katusha and Orica-GreenEdge have become the latest teams to leave the Movement For Credible Cycling (MPCC) this week. It leaves the France-based organisation with just seven teams in the sport’s top tier, with seventeen remaining at ProContinental level.
The latest withdrawals continue the exodus of last year, when five teams left the group, with a variety of reasons cited.
Meanwhile, Katusha have found a delightfully contrived reason to leave, and thus avoid the mandatory self-suspension had they stayed aboard. With the team cleared to race by the UCI Disciplinary Commission in the wake of Luca Paolini and Eduard Vorganov’s positive tests, they claim that they will fall foul of a mandatory participation rule should they self-suspend from racing.
“A suspension of Team KATUSHA during a WorldTour race based on the MPCC Rules would violate the UCI Regulations of mandatory participation and the Disciplinary Commission would then be obliged to sanction the Team.”
The remainder of the press release goes on to state how dismayed the team is with the MPCC for not bringing their team suspension rules (8 days for 2 positive B-Samples) into line with the UCI’s (15 days for 2 positive A-samples), before reaffirming their commitment to clean cycling.
Katusha meanwhile, have taken this nice opportunity to leave the group whose rules, considering the team’s past, are likely to cause them trouble at some point in the future, as well as preventing themselves from missing any important Spring races.
Onto GreenEdge, and their exit is an interesting one, being as they are the only team so far that isn’t departing under a cloud of controversy. Their reasoning is altogether different to any given previously, too.
As general manager Shayne Bannan noted via press release, several initiatives put in place by the MPCC “have now become an integrated part of the rules of the sport.” So if many of the MPCC’s rules have already been incorporated into the UCI’s rulebook, teams see no reason to stay part of what they see as a now largely useless organisation.
The no-needle policy has been adopted by the UCI, as has the idea of team suspensions, while the CIRC Report reccomended that the cortisone rules also carry over. Meanwhile, UCI President Brian Cookson hasalready talked about a possible tramadol ban.
Hark back a handful of years and remember that both teams joined the organisation in order to look good. Katusha joined up whilefighting the UCI in CAS for the right to stay in the WorldTour, whileGreenEdge came aboard at a time when key staff members such as Matt White and Neil Stephens faced suspicions about their pasts.
The MPCC has, in many cases only been useful to teams for a PR boost – as we have seen in the past many find themselves leaving when they are inconvenienced by rules.
Still, it is hard to deny that the organisation is facing increased irrelevancy – yes, teams are jumping ship but the rules they had put in place have been adopted by the UCI. Only there are certainly more fronts to fight on in the war against doping, and no doubt more issues to highlight.
The MPCC’s strong relationship with the ASO is another wrinkle to this situation – Tour de France organiser has said in the past that members would be prioritised for Tour invites. Should the ASO vs UCI standoff remain in place, then the lineup of teams in future ASO races could get more interesting.
In spite of this, the prospect of teams flip-flopping in and out to please Prudhomme doesn’t seem too probable. And would he really refuse invitations to non-members such as Sky and Etixx-QuickStep? It’s unlikely.
Putting these hypotheticals aside, and despite its seemingly increasing redundancy, the MPCC remains an organisation that can make real differences in cycling. We have already seen that it can bring important issues to the fore, and should continue to do so, at least while it still has the power (via the members it holds on to) to have a voice.
Yesterday saw the news that retrospective testing by the UCI had caught Damiano Caruso for taking EPO three years ago, with the sport’s governing body communicating that his sample “had been stored and was reanalysed in light of new scientific developments.”
The positive, which dates to March 2012, could mean a four-year ban for the Sicilian. Aside from the possible career-ending ban, the question on everybody’s lips has been ‘What does this mean for the future of Katusha?’
The questions comes in light of a UCI rule, which was introduced this year. The full rule, which can be found here, reads..
In short, two adverse analytical findings (AAF) from riders or staff on the same team means that the team is collectively punished with a racing ban of between 15 and 45 days. “Notified within a twelve-month period” is important here – the two AAFs don’t necessarily have to come within the same twelve months, so long as the team are notified of them within the same twelve months.
This is the rule that has seen Italian ProContinental team Androni Giocattoli-Sidermec sit out thirty days of racing after the positive tests of Davide Appollonio (EPO on June 14) and Fabio Taborre (FG-4592 on June 21).
Things are different for Katusha though. Even though notification of both positive tests came within a twelve-month period, the fact that Caruso’s positive dates back to 2012 means that a different set of rules apply.
Both the UCI’s rules and the WADA Code (both 25.2) invoke the principle of ‘lex mitior’ – a legal term which means that in cases where a law has been changed, the more lenient of the two will be applied. In this case, the 2012 regulations apply, given that the rule which saw Androni Giocattoli-Sidermec banned was only introduced at the start of this year.
So Katusha will race on, though their Italian contigent is rapidly diminishing. The team called the news of Caruso’s positive a “complete shock”. It’s hard to know exactly how to take this, given that the Russian squad employs Massimo Besnati (worked alongside Ferrari and Ibarguren in the past, was prosecuted for steroid possession in 2001) and Andrei Mikhailov (a convicted criminal thanks to his time at TVM) as doctors.
Are they shocked Caruso was doping, or that he was caught?
Finally, the time has come and the report we have all been waiting for has been released. At 228 pages in length it’s a bit of a slog, and with a great deal of emphasis on the past.
There’s talk of all the familiar faces – the tales of Hein, Lance and Pat are covered at length. We hear about the 1990s and the ‘period of containment’ that focused on limiting the health risks of doping rather than a policy focused on catching every wrongdoer.
Many pages are dedicated to failures in governance that occurred a decade or more ago, and there’s even a section walking us through the history of doping. We all knew how bad the past was – and now we have an official document to prove it. Almost as soon as it was released we saw a number of all-encompassing summaries of the report, including articles by the always great inrng, and Peloton magazine.
Rather than focus on the past though, I want to look at what it the report has to say about the current state of cycling, and what it could mean for the future. Here’s a look.
A turning point in anti-doping
With the cesspool of the 1990s behind us, and the Armstrong years already covered ad nauseum lets fast forward to 2006. The period from that year to 2008 is highlighted by CIRC as a turning point in the fight against doping. “Steady improvements and a growing willingness to combat doping at its roots” are cited.
With Gripper came a raft of changes. Targeted testing was brought in, while more and more out-of-competition tests were carried out. The Cycling Anti-Doping Foundation (CADF) was also introduced during her time at the UCI and funding for anti-doping was increased. An often unnoticed part of the fight – the introduction of post-race chaperones is also noted.
“UCI started to systematically use chaperones in 2008. However, it took some time for the chaperones to serve their purpose. Part of the reason for this, was due to sport-specific logistical obstacles (difficulty of spotting riders, packed finish area). By 2010 it was acknowledged that the chaperone-system was, in principle, working well.”
The biological passport
The biological passport (ABP) was brought in under Gripper’s watch in 2008 and has been hailed as a big advance in anti-doping. We have seen in the past that it isn’t a foolproof tool though, and the report tells us that there are deficiencies for riders to take advantage of – much like the 50% rule, it limits how much riders can dope, rather than eliminating doping altogether.
“In interviews with riders and athlete support personnel it appeared that the basic problem was that athletes would go to the limit of what is detectable and this has not changed. Furthermore, the incentive to try out substances that might give a performance enhancing effect, but are not on the prohibited list is still very present in the peloton.”
Meanwhile there are other problems. The report has found that riders are able to fine-tune doping programmes using ADAMS software – an unintended consequence but a disturbing finding. It is noted that riders can use the software to “assess and monitor their blood values and make sure that they stay within pre-defined parameters through fine-tuning.”
Further criticisms of the passport include the lengthy procedures involved in sanctioning riders (the Menchov and Kreuziger cases are cited), and the “conservative approach” of some of the ABP experts in wanting to pursue ‘doping scenarios’ thanks to the difficulty of analysing nuances in data. While we have seen dopers hide behind excuses like training at altitude or dehydration before, but they can be legitimate reasons for odd blood values. It’s a fact that only makes the job harder for the experts.
So how clean is cycling today?
There were varying responses in the report, and it seems that riders know about as much as we do. According to the CIRC, a common response when asked about how teams was “probably 3 or 4 were clean, 3 or 4 were doping, and the rest were a “don’t know”.”
One rider was asked about cleanliness levels in the peloton and put the figure at 90% but said he thought that “there was little orchestrated team doping” anymore. Another rider felt that 20% were doping, while many stated they just didn’t know who was clean and who was not. Of course, we don’t know who these riders are, so we have little idea of which figure is closer to the mark. And that’s before we get to the question of what riders view as ‘doping’.
Meanwhile new methods of doping such as ozone therapy and AICAR are brought up, while CIRC also includes a staggeringly long list of substances that riders are currently using, or have been during the past few years. There’s even a small section dedicated to the possibility of mechanical doping, something that has been raised several times in the past.
These answers aren’t surprising, but they aren’t heartening either. None of us can safely say which number is more accurate, but we do know that the days of massive gains from doping are gone. The report echoes this, saying that “10-15% gains have become a thing of the past.” Instead, performances are enhanced perhaps 3-5% by new techniques such as microdosing.
So the playing field still isn’t a level one, but going by these figures it’s more level than it used to be.
Despite the heartening numbers, more work still needs to be done, as CIRC notes a number of ways in which riders are still gaining an advantage. The problems with the ABP have been outlined above, but there are further loopholes for riders to take advantage of.
The no-testing window between 11pm and 6am is one. CIRC states that, “riders are confident that they can take a micro-dose of EPO in the evening because it will not show up by the time the doping control officers could arrive to test at 6am.” This is a difficult problem to solve though, with the human rights of riders factoring into the equation.
Often a controversial topic, TUEs are another problem, with interviewees reporting that they are “systematically exploited by some teams and even used as part of performance enhancement programmes.” The abuse of corticoids and insulin in particular raise concern, while there was also a feeling that obtaining a TUE is too easy. One anonymous doctor told CIRC that corticoids were often used for weight loss as opposed to their stated function of pain relief.
Finally, concerns are raised regarding the use and abuse of substances not on WADA’s banned list. One rider talked of a ‘pill system’ he used, which involved him taking up to 30 pills a day, while also reporting the use of tranquilisers and anti-depressants on his team.
The report lists a various array of nutritional and homeopathic substances along with painkillers, caffeine tablets, Viagra and Cialis, with CIRC having been told that all were taken with the sole purpose of substance enhancement in mind. Just think back to the Kovalev brothers to get a glimpse of what this looks like.
Tramadol use has also been in the news in the recent past. It cropped up again here, with interviewees of the opinion that if a rider needed to take it then they shouldn’t be racing. Similar sentiments were recorded regarding corticoids.
So no revelations then, but a lot of information about what is going on in the peloton today. Or at least what is presumed to be going on – the lack of evidence and a reliance on hearsay is a problem. Proof is hard to come by though, and in this case we have to make the best of what we’ve been given.
There are some disappointments – look at the list of names and you only see 16 riders with Chris Froome the only non-retiree. Ten others have declined to be named, but Francesco Reda and Mauro Santambrogio are dead certs. 26 is still a very low number though, and the question of credibility comes up.
In any case, it’s less important to dwell on the individual stories than it is to think about what can be done in response to the report. While everything we have read might not be totally reliable, the raft of ideas that have been proposed seem, on the face of it, to be very useful.
If the UCI has changed – and both the commissioning of this report and the contents within point towards that being the case – then we can cross our fingers and hope that changes like these will be implemented. There’s still a long way to go, but things can get better.
After the three-year investigation into him drew to a close on Thursday, ex-Rabobank and Sky doctor has been banned from the sport for life by USADA as well as the Danish and Dutch anti-doping authorities. USADA were obligated to investigate the Belgian after he was named by Levi Leipheimer during testimony for the US Postal investigation back in 2012. Michael Rasmussen was the other big name involved with the investigation. His testimony (you can view the full USADA report here) implicated teammate Michael Boogerd, now a manager at the new Roompot team, as well as bringing back memories of Stefan Matschiner and the Human Plasma Clinic in Freiburg. However, the most interesting name to crop up was that of Dr Mario Zorzoli, the UCI’s Chief Medical Officer for well over a decade. He has been suspended by cycling’s governing body after being mentioned twice by Rasmussen in testimony, as well as that of Steven Teitler, head of legal affairs at the Dutch anti-doping authority. USADA have passed information from this case to the UCI and CIRC (Cycling Independent Reform Commission), with the UCI due to investigate the doctor. The UCI hasn’t been immune to this sort of thing in the past, with former Presidents Hein Verbruggen and Pat McQuaid accused of at best ‘warning’ riders about doping tests and results, and at worst protecting them. However, this is the first time that a senior UCI member is under investigation for such an impropriety. But wait, there’s more. Zorzoli has been in the headlines before, on quite a few occasions actually. Here’s a look back at the storied career of the UCI’s (possibly soon to be ex) Chief Medical Officer.
Sending warning letters to riders
The UCI has been known in the past to send letters of warning to teams and riders should their test results return suspicious values. Rasmussen and Teitler have said as much with regards to Zorzoli, and we all know about incidents such as the 2001 Tour de Suisse. In 2004, Tyler Hamilton received a letter informing him that during the Tour de Romandie he returned abnormal blood values and that the UCI would be monitoring him more closely in future.
A 2007 article in Spanish newspaper ABC detailed what infamous doctor Eufemiano Fuentes had in his possession at the time of his arrest. Along with a hotel card with rider nicknames, multiple phones and credit cards and some swiss francs (the UCI is based there) was Mario Zorzoli’s business card. Quite why one of the most notorious doping doctors in the sport would have the phone number of the UCI’s Chief Medical Officer is anybody’s guess, and seems to have been largely forgotten.
Another questionable relationship was brought up in David Millar’s book Racing Through The Dark. In 2007 Millar returned from his doping ban with the Spanish Saunier Duval squad, managed by ex-rider Mauro Gianetti, he of perfluorocarbon fame. Shortly after leaving Saunier Duval as PR manager, Stéphane Heulot said this ”Doping is so ingrained in certain managers, like Gianetti, that they can’t conceive of cycling any other way” but here’s what Millar had to say about him.
Further allegations of cosiness with team staff came from Michele Ferrari in 2012. He writes about an incident in 2010 at a Tenerife training camp in which a team doctor was able to phone Zorzoli to arrange the wiping of test results. The effects of altitude distorting blood values was thought to be too much of an inconvenience to the team, and so it was done.
Finally, we come to 2014 and the previous controversy to befall Dr Mario, in which a TUE for Chris Froome was ‘fast-tracked’ and granted by Zorzoli alone, rather than a three-person TUE committee as demanded by the WADA Code. The UCI refused to confirm whether such a setup was in place, but according to its updated TUE regulations, a committee is now in place.
So, not great then. With the good doctor suspended once again, we should all be hoping that this time it will be made permanent. If the UCI’s plans to centralise anti-doping judgements in 2015, doing away with the inconsistent rulings and favouritism we see from national federations, Zorzoli cannot be there. A relic from the McQuaid era, with a record of favourable treatment and dodgy connections, is not someone we need at the UCI in 2015.
Denis Menchov has been handed a two year ban (up until April 2015) and had his results from the 2009, 2011 and 2012 Tours de France stripped thanks to adverse biological passport findings. Of course, this being the UCI, there is controversy involved. Continue reading “Menchov’s secret sanction”→
I’m not sure if anyone remembers my post from last week and the letter to British Cycling’s Head (and my local UCI Management Committee member), Brian Cookson, but I wasn’t very hopeful about the chances of letter-writing bringing about any meaningful change in the higher echelons of the sport. Now, however, it seems that the fan’s voices have been heard. Continue reading “Instigating change at the UCI, follow-up”→